Month: January 2020

Insights+: COVID-19 Healthcare News Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The COVID-19 virus has been named “SARS-CoV-2” (severe acute respiratory syndrome coronavirus 2) and the disease it causes has been named “Coronavirus Disease 2019” (COVID-19). The outbreak of the respiratory disease was first detected […]Read More

Accenture Collaborates with Google Cloud to Support Life Sciences Companies

Shots: Google Cloud will be the technology provider for Accenture’s current and future solutions that is a part of its INTIENT life sciences industry platform. The collaboration is an extension of the partnership between the companies built over the last 8yrs. The collaboration will combine Google’s cloud and AI capabilities with Accenture’s life science capabilities, […]Read More

Microsoft Launches $40M AI Program to Accelerate Health Initiatives Globally

Shots: Microsoft launches a $40M, 5yrs. program AI for Health as a part of AI for Good Initiative program to empower researchers and organizations addressing the world’s toughest challenges in health The program will work to aid academia and non-profit research organizations for their medical research efforts addressing the global health crises and healthcare discrepancies. […]Read More

Inovio Collaborates with Beijing Advaccine to Advance the Development of

Shots: Inovio is currently evaluating INO-4800 vaccine in P-I study assessing its safety and immunogenicity in the US and is supported by a grant of ~$9M from the Coalition for Epidemic Preparedness Innovations (CEPI) The focus of the collaboration is to deploy Advaccine’s expertise to initiate P-I study in China in parallel with its clinical […]Read More

Spring Bank Discontinues the Development of Inarigivir to Treat Patients

Shots: Spring Bank has discontinued the development of Inarigivir soproxil due to the occurrence of one patient death in its P-IIb CATALYST study The discontinuation allows Spring Bank to focus on immuno-oncology & inflammation including its SB 11285 IV STING agonist clinical program in oncology, STING antagonist for inflammatory diseases, and its STING agonist ADC […]Read More

Bayer Report Result of Nubeqa (darolutamide) + ADT in P-III

Shots: The P-III ARAMIS study involves assessing of Nubeqa (600mg, bid) + ADT vs PBO + ADT in 1,509 patients in a ratio (2:1) with nmCRPC who were receiving a concomitant GnRH analog or had a bilateral orchiectomy The P-III ARAMIS study resulted in meeting its 1EPs i.e, improvement in MFS (40.4 vs 18.4mos.) Nubeqa […]Read More